Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04949256
Title Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

esophagus squamous cell carcinoma

Therapies

Cisplatin + Fluorouracil + Pembrolizumab

Cisplatin + Fluorouracil + Lenvatinib + Pembrolizumab

Fluorouracil + Lenvatinib + Leucovorin + Oxaliplatin + Pembrolizumab

Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.